The invention relates to acylhydrazone derivatives of formula (I), which are SGK inhibitors and can be used for the treatment of diseases and afflictions associated with SGK, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systematic and pulmonary hypertension, cardiovascular diseases and kidney diseases and in general for all types of fibroses and inflammatory processes. In said formula: R.sup.1 and R.sup.5 independently of one another represent H, OH, OA, OAc or methyl; R.sup.2, R.sup.3, R.sup.4, R.sup.6, R.sup.7, R.sup.8, R.sup.9 and R.sup.10 independently of one another represent H, OH, OA, OAc, OCF.sub.3, Hal, NO.sub.2, CF.sub.3, A, CN, OSO.sub.2CH.sub.3, SO.sub.2CH.sub.3, NH.sub.2, or COOH; R.sup.11 represents H or CH.sub.3; A represents an alkyl comprising 1, 2, 3, or 4 C atoms; X represents CH.sub.2, CH.sub.2CH.sub.2, OCH.sub.2 or --CH(OH)-- and Hal represents F, Cl, Br or I.